© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 Oxford University Press
ARTICLE |
Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers
Affiliations of authors: S. B. Edge, Roswell Park Cancer Institute, Buffalo, NY; J. C. Niland, R. Ottesen, City of Hope National Medical Center, Duarte, CA; M. A. Bookman, Fox Chase Cancer Center, Philadelphia, PA; R. L. Theriault, M. D. Anderson Cancer Center, Houston, TX; E. Lepisto, National Comprehensive Cancer Network, Rockledge, PA; J. C. Weeks, Dana-Farber Cancer Institute, Boston, MA.
Correspondence to: Stephen B. Edge, MD, Roswell Park Cancer Institute, Elm and Carlton Sts., Buffalo, NY 14263 (e-mail: stephen.edge{at}roswellpark.org).
Background: Ongoing clinical trials are addressing the accuracy and safety of sentinel node biopsy (SNB) in the treatment of breast cancer; however, SNB is already increasingly being used in clinical practice. This study examined the extent and time trends of the use of SNB in stage I and II breast cancer patients. Methods: Clinical data were collected from stage I and II (tumor size 
5.0 cm) breast cancer patients (n = 3003) who were treated at five comprehensive cancer centers between July 1, 1997, and December 31, 2000. Axillary surgery was classified as SNB alone, SNB + axillary node dissection (AND), AND alone, or none. Patterns of use of axillary surgery were summarized as the percentage of patients receiving each surgery type. The statistical significance of time trends for the use of SNB alone was analyzed by logistic regression models. All statistical tests were two-sided. Results: Overall, SNB alone was used in 13% of patients, SNB + AND in 22%, AND alone in 59%, and no axillary surgery in 6%. Use of SNB alone was statistically significantly associated with breast-conserving surgery of both smaller (2 cm) and larger tumors (2–5 cm) (P<.001 for both associations). For stage I cancer patients treated with breast-conserving surgery (n = 1763), use of SNB increased statistically significantly over the study period, from 8% in 1997 to 9%, 14%, 15%, 22%, 42%, and 58% for the next six consecutive 6-month time intervals, respectively. After controlling for center, age, and comorbidity, the odds ratio for the use of SNB alone was 2.30 (95% confidence interval = 1.88 to 2.82) for each 6-month interval (P<.001). Conclusions: Widespread use of SNB outside the clinical trial setting suggests that oncologists at cancer centers in our study have accepted SNB as standard-of-care for the treatment of breast cancer. This acceptance, if it occurs in other cancer centers and community practice, may affect accrual and generalizability of ongoing clinical trials of SNB.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Practice Patterns of Sentinel Node Biopsy at Five Comprehensive Cancer Centers
- David N. Krag and Thomas B. Julian
J Natl Cancer Inst 2003 95: 1498-1499.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  K. A. Vanderveen, R. Ramsamooj, and R. J. Bold A Prospective, Blinded Trial of Touch Prep Analysis versus Frozen Section for Intraoperative Evaluation of Sentinel Lymph Nodes in Breast Cancer Ann. Surg. Oncol., July 1, 2008; 15(7): 2006 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Chen, M. T. Halpern, N. M. Schrag, A. Stewart, M. Leitch, and E. Ward Disparities and Trends in Sentinel Lymph Node Biopsy Among Early-Stage Breast Cancer Patients (1998-2005) J Natl Cancer Inst, April 2, 2008; 100(7): 462 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Edge Early Adoption and Disturbing Disparities in Sentinel Node Biopsy in Breast Cancer J Natl Cancer Inst, April 2, 2008; 100(7): 449 - 450. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Fink, H. Lass, H. Hartleb, W. Jurecka, H. Salzer, and A. Steiner S-Classification of Sentinel Lymph Node Predicts Axillary Nonsentinel Lymph Node Status in Patients with Breast Cancer Ann. Surg. Oncol., March 1, 2008; 15(3): 848 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Wall, M. Florero, N. A. Accortt, R. Allen, M. Kashani-Sabet, E. Morita, and S. P. L. Leong Impact of Multiple Lymphatic Channel Drainage to a Single Nodal Basin on Outcomes in Melanoma Arch Surg, August 1, 2007; 142(8): 753 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Cronin-Fenton, L. A. Ries, L. X. Clegg, and B. K. Edwards Rising Incidence Rates of Breast Carcinoma With Micrometastatic Lymph Node Involvement J Natl Cancer Inst, July 4, 2007; 99(13): 1044 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Vanderveen, D. A. Paterniti, R. L. Kravitz, and R. J. Bold Diffusion of Surgical Techniques in Early Stage Breast Cancer: Variables Related to Adoption and Implementation of Sentinel Lymph Node Biopsy Ann. Surg. Oncol., May 1, 2007; 14(5): 1662 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Newman The Komen Foundation: ACS Outreach Collaboration--Sentinel Lymph Node Biopsy Training for Practicing Surgeons in Remote or Underserved Communities J. Oncol. Pract, November 1, 2006; 2(6): 285 - 287. [Full Text] [PDF]
|
|
|
|
|
|
M. Schaapveld, E. G. E. de Vries, W. T. A. van der Graaf, R. Otter, J. de Vries, and P. H. B. Willemse The Prognostic Effect of the Number of Histologically Examined Axillary Lymph Nodes in Breast Cancer: Stage Migration or Age Association? Ann. Surg. Oncol., April 1, 2006; 13(4): 465 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathanson, R. Slater, D. DeBruyn, A. Kapke, and M. Linden HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis Ann. Surg. Oncol., February 1, 2006; 13(2): 205 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Newman Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer Patients J. Oncol. Pract, November 1, 2005; 1(4): 130 - 133. [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Perez, S. Vidal-Sicart, G. Zanon, M. Velasco, G. Santamaria, A. Palacin, E. Campo, A. Cardesa, and P. L. Fernandez A Practical Approach to Intraoperative Evaluation of Sentinel Lymph Node Biopsy in Breast Carcinoma and Review of the Current Methods Ann. Surg. Oncol., April 1, 2005; 12(4): 313 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Maggard, K. E. Lane, J. B. O'Connell, D. D. Nanyakkara, and C. Y. Ko Beyond the Clinical Trials: How Often Is Sentinel Lymph Node Dissection Performed for Breast Cancer? Ann. Surg. Oncol., January 1, 2005; 12(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Golub, C. L. Bennett, T. Stinson, L. Venta, and M. Morrow Cost Minimization Study of Image-Guided Core Biopsy Versus Surgical Excisional Biopsy for Women With Abnormal Mammograms J. Clin. Oncol., June 15, 2004; 22(12): 2430 - 2437. [Abstract] [Full Text] [PDF]
|
|